{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:21:39Z","timestamp":1772166099969,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T00:00:00Z","timestamp":1699315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T00:00:00Z","timestamp":1699315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Interstitial lung disease (ILD) and pulmonary hypertension (PH) represent the major causes of mortality in systemic sclerosis (SSc). Patients with systemic sclerosis and combined PH and ILD (SSc-PH-ILD) generally have a poor prognosis. Predictors of survival and of potential benefit of treatment are lacking in patients with SSc-PH-ILD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To identify specific plasma protein expression patterns associated with survival in patients with SSc-PH-ILD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>Post-hoc analysis of a prospective multicenter French study in patients with PH-ILD. An untargeted proteomic analysis using mass spectrometry was performed to identify plasma protein changes associated with long-term overall survival in patients with SSc-PH-ILD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty two patients were included in the analysis, of whom 13 died during follow-up (median survival: 76.5\u00a0months). At baseline, survivors had less severe hemodynamic impairment [pulmonary vascular resistance of 4.4 Wood Units (IQR 3\u20135.2) vs. 6.2 Wood Units (IQR 4.2\u201310.7)] and higher carbon monoxide diffusing capacity [median 39% (IQR 35\u201344%) vs. 25% (IQR 22\u201330.5%)], than the 13 patients who died. Seven proteins, associated with haemostasis and fibrosis, were differentially expressed according to patients\u2019 survival. In the survivor group, two proteins were increased (ADAMTS13, SERPIND1) and five were decreased (PTGDS, OLFM1, C7, IGFBP7, FBN1) compared to the non-survivor groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The prognosis of SSc-PH-ILD patients is poor. This proteomic approach found 7 plasma proteins (involved in haemostasis and fibrosis pathways) associated with survival. These potential biomarkers may be good candidates to prognostic enrichment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12931-023-02578-0","type":"journal-article","created":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T01:01:31Z","timestamp":1699318891000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Proteomic biomarkers for survival in systemic sclerosis-associated pulmonary hypertension"],"prefix":"10.1186","volume":"24","author":[{"given":"Valentine","family":"Mismetti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Delavenne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Montani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Souad","family":"Bezzeghoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Delezay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Hodin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Launay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvain","family":"Marchand-Adam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hilario","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edouard","family":"Ollier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martine","family":"Reynaud-Gaubert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"Pastre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Traclet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00e9bastien","family":"Quetant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabrina","family":"Zeghmar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8214-3010","authenticated-orcid":false,"given":"Laurent","family":"Bertoletti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Cottin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,7]]},"reference":[{"key":"2578_CR1","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.rdc.2014.12.005","volume":"41","author":"SR Schoenfeld","year":"2015","unstructured":"Schoenfeld SR, Castelino FV. Interstitial lung disease in scleroderma. Rheum Dis Clin North Am. 2015;41:237\u201348.","journal-title":"Rheum Dis Clin North Am"},{"key":"2578_CR2","first-page":"2230","volume":"34","author":"VD Steen","year":"2007","unstructured":"Steen VD, Lucas M, Fertig N, Medsger TA. Pulmonary arterial hypertension and severe pulmonary fibrosis in systemic sclerosis patients with a nucleolar antibody. J Rheumatol. 2007;34:2230\u20135.","journal-title":"J Rheumatol"},{"key":"2578_CR3","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1056\/NEJMra2005230","volume":"383","author":"M Wijsenbeek","year":"2020","unstructured":"Wijsenbeek M, Cottin V. Spectrum of fibrotic lung diseases. N Engl J Med. 2020;383:958\u201368.","journal-title":"N Engl J Med"},{"key":"2578_CR4","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1002\/art.40027","volume":"69","author":"Y Hao","year":"2017","unstructured":"Hao Y, Hudson M, Baron M, Carreira P, Stevens W, Rabusa C, et al. Early mortality in a multinational systemic sclerosis inception cohort. Arthritis Rheumatol. 2017;69:1067\u201377.","journal-title":"Arthritis Rheumatol"},{"key":"2578_CR5","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.3899\/jrheum.121380","volume":"40","author":"C Muangchan","year":"2013","unstructured":"Muangchan C, Canadian Scleroderma Research Group, Baron M, Pope J. The 15% rule in scleroderma: the frequency of severe organ complications in systemic sclerosis: a systematic review. J Rheumatol. 2013;40:1545\u201356.","journal-title":"J Rheumatol."},{"key":"2578_CR6","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s13075-017-1341-x","volume":"19","author":"K Morrisroe","year":"2017","unstructured":"The Australian Scleroderma Interest Group (ASIG), Morrisroe K, Stevens W, Huq M, Prior D, Sahhar J, et al. Survival and quality of life in incident systemic sclerosis-related pulmonary arterial hypertension. Arthritis Res Ther. 2017;19:122.","journal-title":"Arthritis Res Ther"},{"key":"2578_CR7","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1136\/annrheumdis-2011-200742","volume":"71","author":"FMP Meier","year":"2012","unstructured":"Meier FMP, Frommer KW, Dinser R, Walker UA, Czirjak L, Denton CP, et al. Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis. 2012;71:1355\u201360.","journal-title":"Ann Rheum Dis"},{"key":"2578_CR8","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1002\/art.38029","volume":"65","author":"G Lef\u00e8vre","year":"2013","unstructured":"Lef\u00e8vre G, Dauchet L, Hachulla E, Montani D, Sobanski V, Lambert M, et al. Survival and prognostic factors in systemic sclerosis-associated pulmonary hypertension: a systematic review and meta-analysis. Arthritis Rheum. 2013;65:2412\u201323.","journal-title":"Arthritis Rheum"},{"key":"2578_CR9","first-page":"2200879","volume":"2022","author":"M Humbert","year":"2022","unstructured":"Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, et al. ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2022;2022:2200879.","journal-title":"Eur Respir J"},{"key":"2578_CR10","doi-asserted-by":"publisher","first-page":"170056","DOI":"10.1183\/16000617.0056-2017","volume":"26","author":"D Launay","year":"2017","unstructured":"Launay D, Sobanski V, Hachulla E, Humbert M. Pulmonary hypertension in systemic sclerosis: different phenotypes. Eur Respir Rev. 2017;26:170056.","journal-title":"Eur Respir Rev"},{"key":"2578_CR11","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1002\/art.38390","volume":"66","author":"SI Nihtyanova","year":"2014","unstructured":"Nihtyanova SI, Schreiber BE, Ong VH, Rosenberg D, Moinzadeh P, Coghlan JG, et al. Prediction of pulmonary complications and long-term survival in systemic sclerosis. Arthritis Rheumatol Hoboken NJ. 2014;66:1625\u201335.","journal-title":"Arthritis Rheumatol Hoboken NJ"},{"key":"2578_CR12","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1002\/art.30423","volume":"63","author":"J Le Pavec","year":"2011","unstructured":"Le Pavec J, Girgis RE, Lechtzin N, Mathai SC, Launay D, Hummers LK, et al. Systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease: impact of pulmonary arterial hypertension therapies. Arthritis Rheum. 2011;63:2456\u201364.","journal-title":"Arthritis Rheum"},{"key":"2578_CR13","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/art.41512","volume":"73","author":"L Chauvelot","year":"2021","unstructured":"Chauvelot L, Gamondes D, Berthiller J, Nieves A, Renard S, Catella-Chatron J, et al. Hemodynamic response to treatment and outcomes in pulmonary hypertension associated with interstitial lung disease versus pulmonary arterial hypertension in systemic sclerosis: data from a study identifying prognostic factors in pulmonary hypertension associated with interstitial lung disease. Arthritis Rheumatol. 2021;73:295\u2013304.","journal-title":"Arthritis Rheumatol"},{"key":"2578_CR14","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","volume":"37","author":"N Gali\u00e8","year":"2016","unstructured":"Gali\u00e8 N, Humbert M, Vachiery J-L, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37:67\u2013119.","journal-title":"Eur Heart J"},{"key":"2578_CR15","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202109-2106OC","author":"L Harbaum","year":"2022","unstructured":"Harbaum L, Rhodes CJ, Wharton J, Lawrie A, Karnes JH, Desai AA, et al. Mining the plasma proteome for insights into the molecular pathology of pulmonary arterial hypertension. Am J Respir Crit Care Med. 2022. https:\/\/doi.org\/10.1164\/rccm.202109-2106OC.","journal-title":"Am J Respir Crit Care Med"},{"key":"2578_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223237","author":"S Sanges","year":"2022","unstructured":"Sanges S, Rice L, Tu L, Valenzi E, Cracowski J-L, Montani D, et al. Biomarkers of haemodynamic severity of systemic sclerosis-associated pulmonary arterial hypertension by serum proteome analysis. Ann Rheum Dis. 2022. https:\/\/doi.org\/10.1136\/ard-2022-223237.","journal-title":"Ann Rheum Dis"},{"key":"2578_CR17","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/S2213-2600(17)30161-3","volume":"5","author":"CJ Rhodes","year":"2017","unstructured":"Rhodes CJ, Wharton J, Ghataorhe P, Watson G, Girerd B, Howard LS, et al. Plasma proteome analysis in patients with pulmonary arterial hypertension: an observational cohort study. Lancet Respir Med. 2017;5:717\u201326.","journal-title":"Lancet Respir Med"},{"key":"2578_CR18","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1164\/rccm.202105-1118OC","volume":"205","author":"CJ Rhodes","year":"2022","unstructured":"Rhodes CJ, Wharton J, Swietlik EM, Harbaum L, Girerd B, Coghlan JG, et al. Using the plasma proteome for risk stratifying patients with pulmonary arterial hypertension. Am J Respir Crit Care Med. 2022;205:1102\u201311.","journal-title":"Am J Respir Crit Care Med"},{"key":"2578_CR19","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","volume":"72","author":"F van den Hoogen","year":"2013","unstructured":"van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology\/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2013;72:1747\u201355.","journal-title":"Ann Rheum Dis"},{"key":"2578_CR20","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1164\/rccm.200706-877OC","volume":"177","author":"NSL Goh","year":"2008","unstructured":"Goh NSL, Desai SR, Veeraraghavan S, Hansell DM, Copley SJ, Maher TM, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med. 2008;177:1248\u201354.","journal-title":"Am J Respir Crit Care Med"},{"key":"2578_CR21","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.2517-6161.1996.tb02080.x","volume":"58","author":"R Tibshirani","year":"1996","unstructured":"Tibshirani R. Regression shrinkage and selection via the lasso. J R Stat Soc Ser B Methodol. 1996;58:267\u201388.","journal-title":"J R Stat Soc Ser B Methodol"},{"key":"2578_CR22","unstructured":"KEGG PATHWAY Database: https:\/\/www.genome.jp\/kegg\/pathway.html. Accessed 24 June 2022."},{"key":"2578_CR23","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1086\/690017","volume":"7","author":"KW Prins","year":"2017","unstructured":"Prins KW, Duval S, Markowitz J, Pritzker M, Thenappan T. Chronic use of PAH-specific therapy in World Health Organization Group III Pulmonary Hypertension: a systematic review and meta-analysis. Pulm Circ. 2017;7:145\u201355.","journal-title":"Pulm Circ"},{"key":"2578_CR24","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1056\/NEJMoa2008470","volume":"384","author":"A Waxman","year":"2021","unstructured":"Waxman A, Restrepo-Jaramillo R, Thenappan T, Ravichandran A, Engel P, Bajwa A, et al. Inhaled treprostinil in pulmonary hypertension due to interstitial lung disease. N Engl J Med. 2021;384:325\u201334.","journal-title":"N Engl J Med"},{"key":"2578_CR25","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1097\/MOH.0000000000000169","volume":"22","author":"CB Zander","year":"2015","unstructured":"Zander CB, Cao W, Zheng XL. ADAMTS13 and von Willebrand factor interactions. Curr Opin Hematol. 2015;22:452\u20139.","journal-title":"Curr Opin Hematol"},{"key":"2578_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/20458940211059712","volume":"11","author":"A Ahmed","year":"2021","unstructured":"Ahmed A, Ahmed S, R\u00e5degran G. Plasma ADAMTS13 and von Willebrand factor in diagnosis and prediction of prognosis in pulmonary arterial hypertension. Pulm Circ. 2021;11:1\u201315.","journal-title":"Pulm Circ"},{"key":"2578_CR27","doi-asserted-by":"publisher","first-page":"1801805","DOI":"10.1183\/13993003.01805-2018","volume":"53","author":"M Newnham","year":"2019","unstructured":"Newnham M, South K, Bleda M, Auger WR, Barber\u00e0 JA, Bogaard H, et al. The ADAMTS13\u2013VWF axis is dysregulated in chronic thromboembolic pulmonary hypertension. Eur Respir J. 2019;53:1801805.","journal-title":"Eur Respir J"},{"key":"2578_CR28","first-page":"1518","volume":"74","author":"K Aihara","year":"2010","unstructured":"Aihara K. Heparin cofactor II attenuates vascular remodeling in humans and mice. Circ J Off J Jpn Circ Soc. 2010;74:1518\u201323.","journal-title":"Circ J Off J Jpn Circ Soc"},{"key":"2578_CR29","doi-asserted-by":"publisher","first-page":"eabc7170","DOI":"10.1126\/sciadv.abc7170","volume":"7","author":"L Li","year":"2021","unstructured":"Li L, Liao J, Yuan Q, Hong X, Li J, Peng Y, et al. Fibrillin-1\u2013enriched microenvironment drives endothelial injury and vascular rarefaction in chronic kidney disease. Sci Adv. 2021;7:eabc7170.","journal-title":"Sci Adv"},{"key":"2578_CR30","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.3390\/biomedicines9081058","volume":"9","author":"JM Vel\u00e1zquez-Enr\u00edquez","year":"2021","unstructured":"Vel\u00e1zquez-Enr\u00edquez JM, Santos-\u00c1lvarez JC, Ram\u00edrez-Hern\u00e1ndez AA, Reyes-Jim\u00e9nez E, L\u00f3pez-Mart\u00ednez A, Pina-Canseco S, et al. Proteomic analysis reveals key proteins in extracellular vesicles cargo associated with idiopathic pulmonary fibrosis in vitro. Biomedicines. 2021;9:1058.","journal-title":"Biomedicines"},{"key":"2578_CR31","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1002\/art.30159","volume":"63","author":"E Hsu","year":"2011","unstructured":"Hsu E, Shi H, Jordan RM, Lyons-Weiler J, Pilewski JM, Feghali-Bostwick CA. Lung tissues in patients with systemic sclerosis have gene expression patterns unique to pulmonary fibrosis and pulmonary hypertension. Arthritis Rheum. 2011;63:783\u201394.","journal-title":"Arthritis Rheum"},{"key":"2578_CR32","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1007\/s00380-020-01568-2","volume":"35","author":"H Mutlu","year":"2020","unstructured":"Mutlu H, Kokulu K, Sert ET, \u00c7a\u011flar A. Lipocalin-type prostaglandin D synthase levels are associated with the severity of pulmonary embolism. Heart Vessels. 2020;35:996\u20131002.","journal-title":"Heart Vessels"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-023-02578-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-023-02578-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-023-02578-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T10:15:09Z","timestamp":1730456109000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-023-02578-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,7]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2578"],"URL":"https:\/\/doi.org\/10.1186\/s12931-023-02578-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3161491\/v1","asserted-by":"object"}]},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,7]]},"assertion":[{"value":"11 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The present study was approved by the institutional review board of the Hospices Civils de Lyon. The Comit\u00e9 National d\u2019Informatique et Libert\u00e9 (CNIL), the committee dedicated to privacy, information technology, and civil rights in France, approved the reference methodology MR03 that was used to collect and analyze registry data. Each patients received an information notice and provided written informed consent. All patients gave their consent for their clinical and biological data to be used for research purposes. Patient anonymity has been preserved according to the ethical regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"All the authors that have a conflict of interest (COI) completed an ICMJE DISCLOSURE FORM. All documents have been reported to the <i>Respiratory Research<\/i> journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"273"}}